Dr. Lal Path Labs Ltd. — Important, 30-01-2025: Updates

The Board of Dr. Lal PathLabs has approved the unaudited financial results for the quarter and nine months ended December 31, 2024. The consolidated revenue from operations reached ₹19.16 crore, while the standalone income recorded ₹17.27 crore. Net profit for the quarter amounted to ₹3.67 crore for consolidated results and ₹3.73 crore for standalone results, reflecting a steady performance compared to both the previous quarter and the corresponding period last year.

Additionally, the Board declared a third interim dividend of ₹6 per equity share and reviewed the voluntary liquidation of its wholly-owned subsidiary, Suburban Diagnostics. This strategic decision aims to streamline operations and reduce administrative overheads, paving the way for consolidation with the parent company. The positive outlook from these developments indicates potential growth opportunities for the company, which investors might want to monitor closely.